electroCore Rejoins Ranks of Exploding Speculative COVID-19 Stocks

Health and Healthcare

Published: July 30, 2020 7:03 pm

Whether it’s all speculation or day trading, it seems there is no end to seeing major gains in small and micro-cap stocks that have positive announcements around anything to do with testing, vaccines, treatments or evebn cleaning products that can help win in the battle against COVID-19. One such company which was seeing massive after-hours buying activity on Thursday was electroCore, Inc. (NASDAQ: ECOR).

Traders and investors should be warned that electroCore had a mere $58 million market capitalization as of Thursday’s closing bell. The stock more than doubled on over 10 million shares trading hands in the after-hours. elctroCore has also seen prior pops with similar trading around its other COVID-19 news announcements.

electroCore calls itself a commercial-stage bioelectronic medicine company, but the company’s entire 2019 revenue was just 2.3 million. Thursday’s announcement was additional information about the availability, distribution and pricing for the gammaCore Sapphire™ CV non-invasive vagus nerve stimulation (nVNS) therapy. This is also under the company’s Emergency Use Authorization to use at home or in a healthcare setting.

The company’s target is to acutely treat adult patients with known or suspected COVID-19 cases who are experiencing asthma-related dyspnea and reduced airflow, as well as for whom approved drug therapies are not well tolerated or which are not provide sufficient symptom relief.

According to the company’s statement, the gammaCore Sapphire CV is being made available and the company’s stated goal is to make this process as simple as possible for all of the patients, physicians and hospitals that would like to it. The company has also engaged a specialty pharmacy outfit called Premier Pharmacy Services to support distribution efforts.

24/7 Wall St. has covered electroCore in prior coronavirus coverage, but we would also point out that this stock has trended drastically lower since its 2018 IPO coverage.

On last look, Thursday’s after-hours trading session had a 151% gain to $3.87. This stock also closed at just $1.54 on Thursday’s closing bell, and it has a 52-week range of $0.32 to $5.64.

This looks like yet another speculative micro-cap stocks where speculators and daytraders are entirely on their own.

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.